HES1 and endothelial dysfunction: In conclusion, we showed that the effect of ticagrelor related to the mitigation of endothelial dysfunction in stable CAD/COPD patients may be mediated, at least in part, by its capacity to increase SIRT1 and HES1 mRNAs levels (Supplementary Figure S1).